PALB2 mutations in European familial pancreatic cancer families

Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP, Greenhalf W, Bartsch DK. PALB2 mutations in European pancreatic cancer families.

[1]  W. Foulkes,et al.  Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. , 2009, Gastroenterology.

[2]  J. Heverhagen,et al.  Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer , 2009, Gut.

[3]  Junjie Chen,et al.  PALB2 is an integral component of the BRCA complex required for homologous recombination repair , 2009, Proceedings of the National Academy of Sciences.

[4]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[5]  J. Hopper,et al.  Penetrance Analysis of the PALB2 c.1592delT Founder Mutation , 2008, Clinical Cancer Research.

[6]  R. Hruban,et al.  Advances in counselling and surveillance of patients at risk for pancreatic cancer , 2007, Gut.

[7]  Hans Joenje,et al.  Fanconi anemia is associated with a defect in the BRCA2 partner PALB2 , 2007, Nature Genetics.

[8]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[9]  C. Mathew,et al.  Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer , 2007, Nature Genetics.

[10]  Mariza de Andrade,et al.  The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[11]  Manuel Mattheisen,et al.  Linkage analysis using sex-specific recombination fractions with GENEHUNTER-MODSCORE , 2007, Bioinform..

[12]  E. Fishman,et al.  Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  A. Ziegler,et al.  BRCA2 germline mutations in familial pancreatic carcinoma. , 2003, Journal of the National Cancer Institute.

[14]  Kathleen M Murphy,et al.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. , 2002, Cancer research.

[15]  R C Elston,et al.  Man bites dog? The validity of maximizing lod scores to determine mode of inheritance. , 1989, American journal of medical genetics.

[16]  C. Bonaïti‐pellié,et al.  Effects of misspecifying genetic parameters in lod score analysis. , 1986, Biometrics.